Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review.
Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review. Palliat Med. 2019 Feb 04;:269216319828189 Authors: Norris J, Barker J, Buelens O, Spruijt O Abstract BACKGROUND:: Intractable pruritus affects an estimated 83% of patients with advanced cutaneous T-cell lymphoma. Palliative care strategies to improve outcomes for these patients are lacking. Lignocaine antagonises kappa opioid antagonist-induced scratching in mice models and may relieve cutaneous T-cell lymphoma-pruritus. PRACTICE CHALLENGE:: The aim of this retrospective case series was to evaluate our clinical experience with low-dose continuous subcutaneous infusion lignocaine for intractable pruritus associated with cutaneous T-cell lymphoma, from 2000 to 2015. The study received approval from Retrospective Review Panel, Division Cancer Medicine, 12 October 2015, V1.1. METHOD:: Baseline demographics including cutaneous T-cell lymphoma diagnosis and management, comorbidities, and pruritus-related evaluation including onset, severity, past and current therapies were collected. Response categories (Complete, Partial, No, Unknown) were devised for the study, based on severity of pruritus, impact on sleep and mood. The mean of responses was calculated for each patient and across the series. OUTCOME:: Nineteen patients received continuous subcutaneous infusion lignocaine, in 4...
Date: Thursday, 04 09, 2020; Speaker: Zeynup Gumus, Assistant Professor, Ichan School of Medicine at Mount Sinai; https://cbiit.webex.com/mw3300/mywebex/default.do?
Publication date: Available online 31 March 2020Source: CellAuthor(s): Marcus Ruscetti, John P. Morris, Riccardo Mezzadra, James Russell, Josef Leibold, Paul B. Romesser, Janelle Simon, Amanda Kulick, Yu-jui Ho, Myles Fennell, Jinyang Li, Robert J. Norgard, John E. Wilkinson, Direna Alonso-Curbelo, Ramya Sridharan, Daniel A. Heller, Elisa de Stanchina, Ben Z. Stanger, Charles J. Sherr, Scott W. Lowe
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Andras Komaromy, Balazs Reider, Gabor Jarvas, Andras Guttman
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Yueting Xiong, Chao Shi, Xiaohui Liu, Pengyuan Yang
Authors: Ahmadianpour MV, Mowla J, Sotoodehnejadnematalahi F, Raheb J Abstract Studies on the blood of patients with prostate cancer using Dynamic Light Scattering (DLS) and corona protein size changes have shown that this test is highly specific and sensitive, but this method has not been studied in Iran, and therefore this study intends to perform this procedure using gold nanoparticles in prostate cancer detection. Blood samples of 60 male subjects aged 40-90 years were collected from 20 healthy, 20 benign and 20 prostate cancer patients. Optical scattering changes were measured by the level of gold nanoparticle...
Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs. PMID: 32223298 [PubMed - as supplied by publisher]
Exercise. Eat better. Sleep more. Don ’t worry about things you can’t control. Those are good tips anytime, but especially during a global pandemic, said Dr. Tyler Cooper, president and CEO of Cooper Aerobics and a Cooper Clinic physician. The Dallas institution is in its 50th year. It was founded in 1970 by Cooper’s dad, “Fat her of Aerobics” Kenneth H. Cooper, and has grown into a multi-specialty practice focused on preventive health care and backed by extensive research. In an interview…
CONCLUSION: Our results showed increased percentages of regulatory T cells in pediatric ALL patients despite chemotherapy, which might be compromising the anti-leukemic cellular immune response. PMID: 32224544 [PubMed - in process]
CONCLUSION: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment. PMID: 32224538 [PubMed - in process]
Publication date: Available online 31 March 2020Source: Life SciencesAuthor(s): Zhongqi Liu, Shi Cheng, Ganglan Fu, Fengtao Ji, Chengli Wang, Minghui Cao